Indaptus Therapeutics Inc...
0.87
-0.03 (-3.33%)
At close: Jan 15, 2025, 10:36 AM
undefined%
Bid 0.87
Market Cap 10.45M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.7
PE Ratio (ttm) -0.51
Forward PE n/a
Analyst Buy
Ask 0.88
Volume 18,832
Avg. Volume (20D) 117,757
Open 0.88
Previous Close 0.90
Day's Range 0.86 - 0.90
52-Week Range 0.81 - 3.10
Beta undefined

About INDP

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was fo...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2015
Employees 7
Stock Exchange NASDAQ
Ticker Symbol INDP

Analyst Forecast

According to 2 analyst ratings, the average rating for INDP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 877.01% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago · Source
-4.76%
Indaptus Therapeutics shares are trading lower. Th... Unlock content with Pro Subscription
3 months ago · Source
+12.6%
Indaptus Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.